Elsevier

The Lancet

Volume 340, Issue 8822, 26 September 1992, Pages 748-752
The Lancet

ORIGINAL ARTICLES
Humanised monoclonal antibody therapy for rheumatoid arthritis

https://doi.org/10.1016/0140-6736(92)92294-PGet rights and content

Abstract

Monoclonal antibodies that target T cells have shown some benefit in rheumatoid arthritis although responses have not been long lasting. This is partly due to insufficient therapy consequent upon antibody immunogenicity. Use of humanised antibodies, which are expected to be less foreign to man than conventional rodent antibodies, might overcome this problem. We therefore assessed in a phase 1 open study the potential of a "lymphocyte depleting" regimen of the humanised monoclonal antibody CAMPATH-1H in 8 patients with refractory rheumatoid arthritis.

Apart from symptoms associated with first infusions of antibody, adverse effects were negligible. Significant clinical benefit was seen in 7 patients, lasting for eight months in 1. After one course of therapy, there was no measurable antiglobulin response, although 3 out of 4 patients have become sensitised on retreatment.

Humanisation reduces the immunogenicity of rodent antibodies but anti-idiotype responses may still be seen on repeated therapy, even in patients sharing immunoglobulin allotype with the humanised antibody.

References (23)

  • Ah Puttick et al.

    Genes associated with rheumatoid arthritis and mild inflammatory arthritis. II. Association of HLA with complement C3 and immunoglobulin Gm allotypes

    Ann Rheum Dis

    (1990)
  • Cited by (307)

    • Immune monitoring of patients treated with anti-CD20 therapeutic monoclonals for autoimmune disorders

      2023, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2
    • Modulating T-cell activation with antisense oligonucleotides targeting lymphocyte cytosolic protein 2

      2022, Journal of Autoimmunity
      Citation Excerpt :

      In these patients, modulating T-cell activation represents a promising therapeutic objective, but so far, a limited number of such drugs have been approved. T-cell depletion using monoclonal antibodies was pioneered by the anti-CD52 monoclonal CAMPATH-1H [32], which gave some clinical efficacy in RA patients despite side effects due to long term T-cell depletion [33]. Today indirect T-cell targeting is commonly used in the form of CTLA4-Ig (Abatacept), a soluble receptor binding to co-stimulatory molecules on APCs and is used in many disease settings, including RA [8].

    • Tolerance-inducing medicines in autoimmunity: rheumatology and beyond

      2020, The Lancet Rheumatology
      Citation Excerpt :

      Following renal transplantation, the addition of a rodent IgM CD52 mAb (Campath-1M) to standard immunosuppression reduced acute cellular rejection but increased serious infection risk.37 Studies of alemtuzumab (humanised Campath-1H) in rheumatoid arthritis suggested therapeutic benefit for some participants, often lasting for 6 months or longer after a brief course of therapy.38,39 These trials were curtailed largely because of chronic therapy-induced lymphopenia.

    • Immunotoxicology of Biopharmaceutics

      2018, Comprehensive Toxicology: Third Edition
    View all citing articles on Scopus
    View full text